Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $ETON
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/23/2025 | $17.00 → $33.00 | Buy | H.C. Wainwright |
1/10/2025 | $21.00 | Buy | B. Riley Securities |
1/6/2025 | $15.00 → $17.00 | Buy | H.C. Wainwright |
9/4/2024 | $9.00 | Buy | H.C. Wainwright |
5/6/2024 | $8.00 | Buy | Craig Hallum |
10/14/2021 | $10.00 | Buy | B. Riley Securities |
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the out-licensing of commercial rights to Increlex® in territories outside of the U.S. to Esteve Pharmaceuticals, S.A. ("Esteve"). "Esteve shares Eton's dedication to putting patients first and we're excited to partner with them to distribute this important treatment outside of the U.S. Esteve has the global infrastructure and established presence necessary to successfully commercialize Increlex in countries outside the U.S. This transaction will al
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Management to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight quarter of sequential product sales growthClosed the transformational acquisition of pediatric endocrinology biologic Increlex® and relaunched the product in JanuaryAcquired and relaunched ultra rare disease product Galzin®Licensed U.S. rights to late-stage pipeline candidate Amglidia®, further boosting the Company's pediatric endocrinology pipelineAnnounced positive pivotal clinical study results for ET-600; preparing for an April 2025 NDA submissionManufactured ET-400 launch inventory in preparation
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
- Company's patented desmopressin oral solution successfully passed pivotal bioequivalence study -- Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced positive results from its bioequivalence study of ET-600, a proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. In a bioequivalence study conducted in 75 human subjects, ET-600 demonstrated pharmacokinetic equivalenc
H.C. Wainwright reiterated coverage on Eton Pharmaceuticals with a new price target
H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $33.00 from $17.00 previously
B. Riley Securities initiated coverage on Eton Pharmaceuticals with a new price target
B. Riley Securities initiated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $21.00
H.C. Wainwright reiterated coverage on Eton Pharmaceuticals with a new price target
H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $17.00 from $15.00 previously
Large owner Opaleye Management Inc. bought $79,814 worth of shares (10,000 units at $7.98) (SEC Form 4)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
Large owner Opaleye Management Inc. bought $434,137 worth of shares (62,070 units at $6.99) (SEC Form 4)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
Large owner Opaleye Management Inc. bought $504,875 worth of shares (107,500 units at $4.70) (SEC Form 4)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
SEC Form 4 filed by Director Adams Jennifer Mckie
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
Director Riedel Norbert G exercised 102,400 shares at a strike of $3.65, increasing direct ownership by 171% to 162,145 units (SEC Form 4)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
SEC Form 4 filed by Director Casamento Charles J
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
Eton Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
Eton Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
Eton Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness sector, including significant experience in the pediatric endocrinology specialty. DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Ipek Erdogan-Trinkaus as Chief Commercial Officer (CCO). Ms. Erdogan-Trinkaus brings to the Company broad commercial experience in the pharmaceutical
Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer
DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through the end of May to ensure a smooth transition. "We are pleased to welcome James to the Eton team. He brings a wealth of experience managing the finance and accounting activities for some of the most successful companies in the industry. We look forward to benefiting from his financial expertise as we
Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director
LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the "Board"). He will hold office as an independent director until the next annual meeting of shareholders, or until his successor has been elected or appointed. Mr. Maier has also been appointed as a member of the Audit Committee and Corporate Governance and Nominating Committee and Chair of the Compensation Committee. Mr. Maier joins Small Pharma with over 30 years' ex
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Management to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight quarter of sequential product sales growthClosed the transformational acquisition of pediatric endocrinology biologic Increlex® and relaunched the product in JanuaryAcquired and relaunched ultra rare disease product Galzin®Licensed U.S. rights to late-stage pipeline candidate Amglidia®, further boosting the Company's pediatric endocrinology pipelineAnnounced positive pivotal clinical study results for ET-600; preparing for an April 2025 NDA submissionManufactured ET-400 launch inventory in preparation
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement to acquire Increlex® (mecasermin injection)Q3 2024 product sales increased 40% over Q3 2023, representing 15th straight quarter of sequential product sales growthProduced positive quarterly GAAP net income from product sales for first time in company historyGenerated cash from operations of $2.9 million in Q3 2024Granted additional patent for ET-400Management to hold conference call today at 4:30pm ET DEER PARK, Ill., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical c
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial in (Audio Only) Toll-free: 888-596-4144 Non-toll free: 646-968-2525 Access Code: 1144771 Webcast: Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions fr
SEC Form SC 13G filed by Eton Pharmaceuticals Inc.
SC 13G - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
Amendment: SEC Form SC 13G/A filed by Eton Pharmaceuticals Inc.
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SEC Form SC 13D/A filed by Eton Pharmaceuticals Inc. (Amendment)
SC 13D/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)